Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 15/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038289 | 1.00 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL31034788 | 1.00 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL27378658 | 0.99 | PDE5A (0.98) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL27357104 | 0.99 | PDE5A (0.98) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27376208 | 0.99 | PDE5A (0.98) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL27355410 | 0.93 | PDE5A (0.86) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7495950 | 0.91 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7499068 | 0.87 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13192079 | 0.86 | PDE5A (0.76) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13191863 | 0.86 | PDE5A (0.76) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080193385-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | MAIBACH TODD | 2008-08-14 | — | — | US | claimed |
| US-20060276440-A1 | Treatment of inflammatory disorders | BIONAUT PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | claimed |
| WO-2006074192-A2 | TREATMENT OF INFLAMMATORY DISORDERS | BIONAUT PHARMACEUTICALS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-6586478-B2 | Administering nitrogen oxide mimetic | CELLEGY CANADA (CA) | 2003-07-01 | — | — | US | claimed |
| US-20020006930-A1 | Method for stimulating liver regeneration | UNIVERISTY OF MANITOBA (CA) | 2002-01-17 | — | — | US | claimed |
| WO-2024136338-A1 | COMPOSITION COMPRISING N-BENZYLQUINAZOLINE-4-AMINE COMPOUND FOR PREVENTING OR TREATING OBESITY OR LIPID-ASSOCIATED METABOLIC DISORDERS | 연세대학교 산학협력단 | 2024-06-27 | — | — | WO | disclosed |
| US-9393244-B2 | Increasing parkin activity by administering a deubiquitinating enzyme inhibitor | GEORGETOWN UNIVERSITY (US) | 2016-07-19 | — | — | US | disclosed |
| US-9393244-B2 | Increasing parkin activity by administering a deubiquitinating enzyme inhibitor | GEORGETOWN UNIVERSITY (US) | 2016-07-19 | — | — | US | disclosed |
| US-20140271668-A1 | INCREASING PARKIN ACTIVITY BY ADMINISTERING A DEUBIQUITINATING ENZYME INHIBITOR | GEORGETOWN UNIVERSITY (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271668-A1 | INCREASING PARKIN ACTIVITY BY ADMINISTERING A DEUBIQUITINATING ENZYME INHIBITOR | GEORGETOWN UNIVERSITY (US) | 2014-09-18 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120258975-A1 | Potent Small Molecule Inhibitors of Autophagy, and Methods of Use Thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2012-10-11 | — | — | US | disclosed |
| US-20020006930-A1 | Method for stimulating liver regeneration | UNIVERISTY OF MANITOBA (CA) | 2002-01-17 | — | — | US | disclosed |
| EP-0607439-B1 | NITROGENOUS HETEROCYCLIC COMPOUND | EISAI CO LTD (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6046206-A | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives | CELL PATHWAYS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5693652-A | Benzimidazoles for ischemic heart conditions | EISAI CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| CN-1071164-A | Nitrogen-containing heterocycle compound | EISAI CO LTD (JP) | 1993-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276440-A1 | Treatment of inflammatory disorders | NR3C1, OXGR1, IRAK2 | PDE5A 4471/4885MEN1 4711/4885KMT2A 3138/4885 |
| US-20120258975-A1 | Potent Small Molecule Inhibitors of Autophagy, and Methods of Use Thereof | ATG7, BECN1, SQSTM1 | PDE5A 3288/4885MEN1 2998/4885KMT2A 4516/4885 |
| US-20140271668-A1 | INCREASING PARKIN ACTIVITY BY ADMINISTERING A DEUBIQUITINATING ENZYME INHIBITOR | UBQLN1, UBQLN2, PARK7 | PDE5A 2136/4885MEN1 3512/4885KMT2A 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.